8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 22, 2008

ThermoGenesis Corp.
__________________________________________
(Exact name of registrant as specified in its charter)

Delaware	333-82900	94-3018487
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
2711 Citrus Rd., Rancho Cordova, California		95742
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

Registrant’s telephone number, including area code: 916-858-5100

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On February 22, 2008, the Company announced that it has initiated a voluntary recall of certain lots of its AXP(TM) AutoXpress(TM) Platform bag sets, as described in the attached press release dated February 22, 2008.

Item 9.01 Financial Statements and Exhibits.

99.1 Press release dated February 22, 2008, titled "ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets"

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ThermoGenesis Corp.
February 22, 2008	By:	Matthew T. Plavan
		Name: Matthew T. Plavan
		Title: Chief Financial Officer

Exhibit Index

Exhibit No.	Description
99.1	Press release dated February 22, 2008, titled "ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets"

EX-99.1

THERMOGENESIS CORP. ANNOUNCES VOLUNTARY RECALL OF SELECTED LOTS OF AXP BAG SETS

RANCHO CORDOVA, CA, (February 22, 2008)—ThermoGenesis Corp. (NASDAQ: KOOL), said today that it has initiated a voluntary recall of certain lots of its AXP™ AutoXpress Platform™ (AXP) bag sets.

The Company said it has discovered in a document review process that some lots of the bag sets were distributed prior to the performance of pyrogen testing, which is a manufacturing release criterion.

The Company said that this recall is not the result of any customer complaints or reports of patient safety issues. The Company also believes that the potential for any contamination is low. What this means for AXP customers is they are being asked to return inventory from recalled lots for additional testing at ThermoGenesis and they may be required to perform an additional test before releasing a cord blood unit for transplant.

The Company is cooperating fully with the U.S. Food and Drug Administration and will provide updates as new information becomes available and if it believes there will be a potential material impact on the Company’s performance.

This press release, including statements regarding financial information for future
periods, contain forward-looking statements, and such statements are made pursuant to the safe
harbour provisions of the Private Securities Litigation Reform Act of 1995. These statements
involve risks and uncertainties that could cause actual outcomes to differ materially from those
contemplated by the forward-looking statements. Several factors, including timing of FDA approvals,
changes in customer forecasts, our failure to meet customers’ purchase order and quality
requirements, supply shortages, production delays, changes in the markets for customers’ products,
introduction timing and acceptance of our new products scheduled for fiscal year 2008, and
introduction of competitive products and other factors beyond our control, could result in a
materially different revenue outcome and/or in our failure to achieve the revenue levels we expect
for fiscal 2008. A more complete description of these and other risks that could cause actual
events to differ from the outcomes predicted by our forward looking statements is set forth under
the caption “Risk Factors” in our annual report on Form 10-K and other reports we file with the
Securities and Exchange Commission from time to time, and you should consider each of those factors
when evaluating the forward looking statements.

ThermoGenesis Corp.
Web site: http://www.thermogenesis.com
Contact: Investor Relations
+1-916-858-5107, or
ir@thermogenesis.com